Merck’s Pimicotinib NDA Accepted for Review by China’s CDE
German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for...
CSPC Pharma’s SYS6040 ADC Gains FDA Clinical Trial Approval
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...
State Council Issues Opinions to Advance Shenzhen’s Healthcare Reforms
The General Office of the State Council released the “Opinions on Further Advancing Shenzhen’s Comprehensive...
Eisai’s Urece Arrives in Shanghai, Poised for Chinese Market Entry
Eisai’s (TYO: 4523) China unit announced that the first batch of its innovative drug Urece...
Sanofi to Ship Beyfortus Ahead of RSV Season, Ensuring Global Availability
France-based Sanofi (NASDAQ: SNY) announced plans to commence shipments of Beyfortus (nirsevimab) in early Q3...
Boai NKY’s LYC001 Receives Clinical Approval in China for Advanced Solid Tumors
China-based Boai NKY Medical Holdings Ltd (SHE: 300109) announced that its joint venture company, Beijing...
Sino Biopharmaceutical’s TQB2868 Approved for Phase III Trial in Metastatic Pancreatic Cancer
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...
Ocumension Therapeutics Gains CDE Approval for Phase III Presbyopia Trial
Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation...
Jiangxi Rimag Plans Acquisition of Changsha Zhongya Medical for RMB 29.5 Million
China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced plans to acquire 100% stake in...
Biogen Launches Qalsody in China for SOD1-ALS Treatment
US-based Biogen (NASDAQ: BIIB) officially launched Qalsody (tofersen) in China this week. The drug, the...
Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH
Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise...
China Expands Medical Insurance Coverage in New State Council Guidelines
The General Office of the State Council released the “Guidelines on Further Safeguarding and Improving...
WuXi Biologics Commences Construction on Microbial Production Base in Chengdu
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced the official...
Sihuan Pharma’s Xuanyuening Granted New Indication Review in China
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Johnson & Johnson Launches Tremfya IV in China for Inflammatory Bowel Diseases
US-based Johnson & Johnson (J&J; NYSE: JNJ) announced the commercial launch of Tremfya (guselkumab) intravenous...
Deep Surgery Secures Pre-Series A Funding for Microsurgery Robot Expansion
Guangzhou-based microsurgery robot developer Deep Surgery has secured “tens of millions” of renminbi in a...
ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as...
Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...
Suzhou Sinus Medtech Wins FDA Breakthrough Designation for oHCM Ablation System
Suzhou Sinus Medical Technologies Co., Ltd., a China-based medical device innovator, announced that its in-house...
Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...